Kura Oncology Inc (NASDAQ:KURA) shares, rose in value on Thursday, March 06, with the stock price up by 4.48% to the previous day’s close as strong demand from buyers drove the stock to $7.70.
Actively observing the price movement in the last trading, the stock closed the session at $7.37. Referring to stock’s 52-week performance, its high was $24.17, and the low was $6.98. On the whole, KURA has fluctuated by -13.39% over the past month.
With the market capitalization of Kura Oncology Inc currently standing at about $621.81 million, investors are eagerly awaiting this quarter’s results, scheduled for in April.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 36.38M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that KURA’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of KURA currently trading nearly -4.18% and -4.87% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 43.81, while the 7-day volatility ratio is showing 6.12% which for the 30-day chart, stands at 5.89%. Furthermore, Kura Oncology Inc (KURA)’s beta value is 0.78, and its average true range (ATR) is 0.45.
A comparison of Kura Oncology Inc (KURA) with its peers suggests the former has fared considerably weaker in the market. KURA showed an intraday change of 4.48% in last session, and over the past year, it shrunk by -63.87%%.
Data on historical trading for Kura Oncology Inc (NASDAQ:KURA) indicates that the trading volumes over the past 3 months, they’ve averaged 1.67 million. According to company’s latest data on outstanding shares, there are 78.23 million shares outstanding.
Nearly 6.94% of Kura Oncology Inc’s shares belong to company insiders and institutional investors own 96.11% of the company’s shares. The stock has fallen by -11.60% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the KURA stock heading into the next quarter.
